A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01037907 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

173

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Pleneva TM BGC20-0134
DRUG: Placebo

Sponsor

Boston Scientific Corporation